SG11202109857UA - Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia - Google Patents
Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemiaInfo
- Publication number
- SG11202109857UA SG11202109857UA SG11202109857UA SG11202109857UA SG 11202109857U A SG11202109857U A SG 11202109857UA SG 11202109857U A SG11202109857U A SG 11202109857UA SG 11202109857U A SG11202109857U A SG 11202109857UA
- Authority
- SG
- Singapore
- Prior art keywords
- anemia
- antagonists
- treatment
- acetylcholine receptor
- receptor subtype
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823214P | 2019-03-25 | 2019-03-25 | |
| PCT/US2020/023989 WO2020198054A1 (en) | 2019-03-25 | 2020-03-20 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109857UA true SG11202109857UA (en) | 2021-10-28 |
Family
ID=72608578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109857U SG11202109857UA (en) | 2019-03-25 | 2020-03-20 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220185821A1 (en) |
| EP (1) | EP3946321A4 (en) |
| JP (2) | JP7558187B2 (en) |
| KR (1) | KR20210144697A (en) |
| CN (1) | CN113613650A (en) |
| AU (1) | AU2020247812A1 (en) |
| BR (1) | BR112021019189A2 (en) |
| CA (1) | CA3132381A1 (en) |
| IL (1) | IL286617A (en) |
| MX (1) | MX2021011588A (en) |
| SG (1) | SG11202109857UA (en) |
| WO (1) | WO2020198054A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6500837B2 (en) * | 2000-09-22 | 2002-12-31 | Warner-Lambert Company | Fused ring system containing indole as M4 selective aza-anthracene muscarinic receptor antagonists |
| WO2007136300A2 (en) * | 2006-05-23 | 2007-11-29 | Alla Chem, Llc | Substituted indoles and a method for the production and use thereof |
| US20130059783A1 (en) * | 2010-03-12 | 2013-03-07 | Johan Flygare | Compositions and methods for expanding bfu-e cells |
| EP3490542A4 (en) | 2016-07-26 | 2020-07-08 | Flagship Pioneering Innovations V, Inc. | Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response |
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Drug combinations for protecting against neuronal cell death |
-
2020
- 2020-03-20 WO PCT/US2020/023989 patent/WO2020198054A1/en unknown
- 2020-03-20 KR KR1020217029823A patent/KR20210144697A/en unknown
- 2020-03-20 EP EP20776829.2A patent/EP3946321A4/en active Pending
- 2020-03-20 JP JP2021553300A patent/JP7558187B2/en active Active
- 2020-03-20 MX MX2021011588A patent/MX2021011588A/en unknown
- 2020-03-20 AU AU2020247812A patent/AU2020247812A1/en active Pending
- 2020-03-20 SG SG11202109857U patent/SG11202109857UA/en unknown
- 2020-03-20 US US17/442,926 patent/US20220185821A1/en active Pending
- 2020-03-20 BR BR112021019189A patent/BR112021019189A2/en unknown
- 2020-03-20 CA CA3132381A patent/CA3132381A1/en active Pending
- 2020-03-20 CN CN202080024089.9A patent/CN113613650A/en active Pending
-
2021
- 2021-09-23 IL IL286617A patent/IL286617A/en unknown
-
2024
- 2024-05-20 JP JP2024081788A patent/JP2024102364A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020198054A1 (en) | 2020-10-01 |
| JP2024102364A (en) | 2024-07-30 |
| MX2021011588A (en) | 2021-12-15 |
| JP2022525293A (en) | 2022-05-12 |
| EP3946321A1 (en) | 2022-02-09 |
| JP7558187B2 (en) | 2024-09-30 |
| AU2020247812A1 (en) | 2021-09-30 |
| EP3946321A4 (en) | 2023-03-08 |
| US20220185821A1 (en) | 2022-06-16 |
| BR112021019189A2 (en) | 2021-11-30 |
| CA3132381A1 (en) | 2020-10-01 |
| KR20210144697A (en) | 2021-11-30 |
| CN113613650A (en) | 2021-11-05 |
| IL286617A (en) | 2021-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273924A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| IL276411A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| IL274062A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| IL271805A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP4413985A3 (en) | Pharmaceutical compounds | |
| CL2008000119A1 (en) | COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA. | |
| IL274742A (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| EP3697781C0 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| CL2007001042A1 (en) | COMPOUNDS DERIVED FROM THIOXANTINE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE IN THE TREATMENT OF NEUROINFLAMATORY DISORDERS AS MULTIPLE SCLEROSIS, PARKINSON, IN ATEROSCLEROTIC DISORDERS, CARDIO- AND CEREBROVASCULAR, DES | |
| EP3732163A4 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2016066634A3 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer | |
| JP2019535799A5 (en) | ||
| IL272952A (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
| EP3810614C0 (en) | Bridged compounds as agonists of the muscarinic m1 and/or m4 receptor | |
| IL281809A (en) | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | |
| IL288010A (en) | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies | |
| HUE057257T2 (en) | Liquid composition for use in the treatment of gastroesophageal reflux | |
| EP3846806A4 (en) | Muscarinic acetylcholine m1 receptor antagonists | |
| EP4054620C0 (en) | Semaglutide in the treatment of alzheimer's dementia | |
| GB201802307D0 (en) | CD36 antagonists for use in melanoma treatment | |
| EP4037677A4 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP1747219A4 (en) | Muscarinic acetylcholine receptor antagonists field of the invention | |
| WO2018094106A3 (en) | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES | |
| ZA202213427B (en) | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof | |
| IL286617A (en) | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia |